We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Novel Blood Test Could Cut Hospital Stays for Children with Cancer

By LabMedica International staff writers
Posted on 21 Mar 2022

High temperatures are common in children undergoing treatment for cancer due to their lowered immune system. The commonest approach is to keep children in hospital for up to a week while antibiotics are administered in case the fever is a symptom of a serious infection like sepsis. A new blood test could help to safely cut hospital stays for children with cancer who develop a fever, according to a new study.

The study, by researchers from the University of York (York, UK) and Hull York Medical School (York, UK) reveals the blood test can help doctors to distinguish between children whose fever is a sign of serious illness and those who are safe to go home. The results of the study, which involved 28 children with cancer, show that using the blood test in combination with a new protocol to identify children that are safe to go home, cuts their average stay in hospital down to two days, with some able to leave in as little as eight hours. The researchers believe that this change will make an enormous difference to children with cancer and their families, easing mental health and financial burdens. The test diagnoses serious infections by looking at levels of the biomarker procalcitonin in the blood. Those children with low levels often had their antibiotics stopped more quickly and went home earlier.

"Frequent fevers are a distressing and sometimes life-threatening complication of childhood cancer. Our study shows that procalcitonin blood tests could make a big difference to children who don’t have a serious infection, allowing them to go home earlier to be with their families, cutting unnecessary treatment with antibiotics and reducing an already intense mental and physical toll," said Dr. Bob Phillips from the Centre for Reviews and Dissemination at the University of York and Hull York Medical School. "These promising results and the willingness of families to take part in this research mean we can now apply for further funding in order to carry out a large-scale study."

Related Links:
University of York 
Hull York Medical School 

Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Lyme Disease Test
Lyme IgG/IgM Rapid Test Cassette
New
Mycoplasma Pneumoniae Virus Test
Mycoplasma Pneumoniae Virus Detection Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The study investigated D-dimer testing in patients who are at higher risk of pulmonary embolism (Photo courtesy of Adobe Stock)

D-Dimer Testing Can Identify Patients at Higher Risk of Pulmonary Embolism

Pulmonary embolism (PE) is a commonly suspected condition in emergency departments (EDs) and can be life-threatening if not diagnosed correctly. Achieving an accurate diagnosis is vital for providing effective... Read more

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more

Microbiology

view channel
Image: Schematic representation illustrating the key findings of the study (Photo courtesy of UNIST)

Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours

Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.